Platelet alpha-2-adrenergic dysfunction in negative symptom schizophrenia: A preliminary study
dc.contributor.author | Rosen, Jules | en_US |
dc.contributor.author | Silk, Kenneth R. | en_US |
dc.contributor.author | Rice, Henry E. | en_US |
dc.contributor.author | Smith, Charles B. | en_US |
dc.date.accessioned | 2006-04-07T19:05:44Z | |
dc.date.available | 2006-04-07T19:05:44Z | |
dc.date.issued | 1985-05 | en_US |
dc.identifier.citation | Rosen, Jules, Silk, Kenneth R., Rice, Henry E., Smith, Charles B. (1985/05)."Platelet alpha-2-adrenergic dysfunction in negative symptom schizophrenia: A preliminary study." Biological Psychiatry 20(5): 539-545. <http://hdl.handle.net/2027.42/25689> | en_US |
dc.identifier.uri | http://www.sciencedirect.com/science/article/B6T4S-482YS43-48/2/18a193f6f1e3092f96b63519cdf999f3 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/25689 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=2985130&dopt=citation | en_US |
dc.description.abstract | The specific binding to platelet membranes (Bmax) of 3H-clonidine, and alpha-2 agonist, and 3H-yohimbine, an alpha-2 antagonist, was measured in nine drug-free male schizophrenic patients and repeated after 2 weeks of chlorpromazine (CPZ) treatment. Patients with a lower pretreatment Bmax for 3H-clonidine showed a significantly smaller change in Bmax after treatment, less improvement in their clinical state, as indicated by the change in the Global Assessment Scale (GAS), and a lower posttreatment GAS. Also, they had a significantly higher score for negative symptoms on the Affect Rating Scale both before and after treatment. These findings suggest that schizophrenic patients with relatively subsensitive platelet alpha-2-adrenergic receptors, as measured by 3H-clonidine binding, tend to have more negative symptoms and a diminished alpha receptor binding response and diminished clinical response to CPZ. There were no clinical correlations to 3H-yohimbine binding. | en_US |
dc.format.extent | 377658 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Elsevier | en_US |
dc.title | Platelet alpha-2-adrenergic dysfunction in negative symptom schizophrenia: A preliminary study | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Psychiatry | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Psychiatry, University of Michigan Medical School, USA; Ann Arbor VAMC, University of Michigan Medical School, USA | en_US |
dc.contributor.affiliationum | University of Michigan, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationum | Department of Pharmacology, University of Michigan Medical School, USA | en_US |
dc.contributor.affiliationother | The VA Medical Center and the University of Pittsburgh Medical School, Pittsburgh, PA, USA | en_US |
dc.identifier.pmid | 2985130 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/25689/1/0000243.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1016/0006-3223(85)90025-3 | en_US |
dc.identifier.source | Biological Psychiatry | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.